Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company Read more…
World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), today announced the signing of a licensing agreement with Amgen to develop next generation ADCs. Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select […]
Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and […]
It’s nearly the end of 2022! It was an exciting year for Optimum’s clients which demonstrated the resilience and creativity that has made the life sciences industry so successful. We have outlined below a small fraction of the activity that has kept us busy this year: Deal, deals, deals As usual, 2022 was a year […]
